Eli Lilly and Company $LLY Stock Holdings Boosted by Kestra Private Wealth Services LLC

Key Points

• Kestra Private Wealth Services increased its Eli Lilly stake by 1.3% in the third quarter, adding 752 shares to hold 57,167 shares valued at about $66.1 million. Institutional investors collectively own 82.53% of the stock.
• Lilly reported quarterly earnings of $7.48 per share, beating the $5.71 analyst consensus, while revenue of $24.4 billion exceeded estimates and rose 38.6% year over year.
• Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $1,404.14, though the article also flags GLP-1 price competition as a potential risk to growth.

Kestra Private Wealth Services LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 57,167 shares of the company's stock after buying an additional 752 shares during the quarter. Eli Lilly and Company comprises 0.7% of Kestra Private Wealth Services LLC's portfolio, making the stock its 23rd biggest position. Kestra Private Wealth Services LLC's holdings in Eli Lilly and Company were worth $66,147,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Jacksonville Wealth Management LLC lifted its holdings in Eli Lilly and Company by 2.6% during the third quarter. Jacksonville Wealth Management LLC now owns 518 shares of the company's stock worth $599,000 after acquiring an additional 13 shares in the last quarter. Guardian Wealth Management Inc. grew its stake in Eli Lilly and Company by 2.9% in the third quarter. Guardian Wealth Management Inc. now owns 8,049 shares of the company's stock valued at $9,314,000 after acquiring an additional 226 shares during the period. Boston Trust Walden Corp increased its holdings in shares of Eli Lilly and Company by 1.0% in the third quarter. Boston Trust Walden Corp now owns 3,328 shares of the company's stock worth $3,851,000 after acquiring an additional 33 shares in the last quarter. Gordian Advisors LLC increased its holdings in shares of Eli Lilly and Company by 11.7% in the third quarter. Gordian Advisors LLC now owns 286 shares of the company's stock worth $331,000 after acquiring an additional 30 shares in the last quarter. Finally, Chicago Partners Investment Group LLC increased its holdings in shares of Eli Lilly and Company by 3.7% in the third quarter. Chicago Partners Investment Group LLC now owns 18,887 shares of the company's stock worth $24,051,000 after acquiring an additional 671 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

LLY opened at $1,368.85 on Friday. The business's 50-day moving average price is $1,211.30 and its two-hundred day moving average price is $1,099.50. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,453.00. The company has a market capitalization of $1.29 trillion, a price-to-earnings ratio of 44.43, a P/E/G ratio of 1.77 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts' consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same quarter in the previous year, the firm posted $7.02 earnings per share. The firm's revenue for the quarter was up 38.6% on a year-over-year basis. Equities analysts expect that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 22.46%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported encouraging Phase 3 results for investigational retatrutide in people with knee osteoarthritis and obesity, including substantial weight and knee-pain reductions. New data also showed benefits from combining Zepbound with Taltz in adults with psoriatic arthritis and obesity, supporting the potential of Lilly’s obesity franchise across additional conditions. Lilly ACR Convergence data
• Positive Sentiment: Recent earnings momentum remains a support: Lilly beat Q3 estimates and raised its outlook, reinforcing expectations for strong demand for its medicines. Commentary also presents LLY as a potential defensive holding amid the technology selloff, which could attract investors seeking growth outside tech. LLY as a potential safe haven
• Negative Sentiment: Investors are also watching growing price competition in the GLP-1 market. Lower realized prices could temper the revenue and profit growth investors expect from Lilly’s highly valued obesity-drug business. GLP-1 price competition

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. The Goldman Sachs Group reaffirmed a "buy" rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an "overweight" rating in a research report on Monday. BMO Capital Markets reissued an "outperform" rating and set a $1,650.00 target price on shares of Eli Lilly and Company in a research note on Friday, October 30th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, October 31st. Finally, Sanford C. Bernstein restated an "outperform" rating and set a $1,450.00 target price on shares of Eli Lilly and Company in a report on Monday, October 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $1,404.14.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the sale, the executive vice president directly owned 4,137 shares of the company's stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 13,500 shares of company stock valued at $17,020,770. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.